334 related articles for article (PubMed ID: 9869566)
1. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
Mouneimné H; Robert J; Jarlier V; Cambau E
Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
[TBL] [Abstract][Full Text] [Related]
2. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
[TBL] [Abstract][Full Text] [Related]
3. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
Akasaka T; Tanaka M; Yamaguchi A; Sato K
Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.
Jalal S; Wretlind B
Microb Drug Resist; 1998; 4(4):257-61. PubMed ID: 9988043
[TBL] [Abstract][Full Text] [Related]
5. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
Lei YC; Wang HB; Sun ZY; Shen ZY
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
[TBL] [Abstract][Full Text] [Related]
6. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
Lee JK; Lee YS; Park YK; Kim BS
Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii.
Navia MM; Ruiz J; Ribera A; de Anta MT; Vila J
J Antimicrob Chemother; 1999 Dec; 44(6):743-8. PubMed ID: 10590274
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
Chen JY; Siu LK; Chen YH; Lu PL; Ho M; Peng CF
Microb Drug Resist; 2001; 7(1):47-53. PubMed ID: 11310803
[TBL] [Abstract][Full Text] [Related]
9. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
Ling JM; Chan EW; Lam AW; Cheng AF
Antimicrob Agents Chemother; 2003 Nov; 47(11):3567-73. PubMed ID: 14576119
[TBL] [Abstract][Full Text] [Related]
10. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
Shultz TR; Tapsall JW; White PA
Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
[TBL] [Abstract][Full Text] [Related]
11. The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran.
Nouri R; Ahangarzadeh Rezaee M; Hasani A; Aghazadeh M; Asgharzadeh M
Braz J Microbiol; 2016; 47(4):925-930. PubMed ID: 27522930
[TBL] [Abstract][Full Text] [Related]
12. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
13. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
[TBL] [Abstract][Full Text] [Related]
14. Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.
Cambau E; Perani E; Dib C; Petinon C; Trias J; Jarlier V
Antimicrob Agents Chemother; 1995 Oct; 39(10):2248-52. PubMed ID: 8619577
[TBL] [Abstract][Full Text] [Related]
15. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
Taba H; Kusano N
Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
[TBL] [Abstract][Full Text] [Related]
16. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
[TBL] [Abstract][Full Text] [Related]
17. gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon.
Salma R; Dabboussi F; Kassaa I; Khudary R; Hamze M
J Infect Chemother; 2013 Feb; 19(1):77-81. PubMed ID: 22821356
[TBL] [Abstract][Full Text] [Related]
18. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
Pan XS; Ambler J; Mehtar S; Fisher LM
Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility.
Valdezate S; Vindel A; Echeita A; Baquero F; Cantó R
Antimicrob Agents Chemother; 2002 Mar; 46(3):665-71. PubMed ID: 11850246
[TBL] [Abstract][Full Text] [Related]
20. Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.
Bébéar CM; Renaudin H; Charron A; Bové JM; Bébéar C; Renaudin J
Antimicrob Agents Chemother; 1998 Sep; 42(9):2304-11. PubMed ID: 9736554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
